验证数据展示
经过测试的应用
| Positive WB detected in | HeLa cells, HepG2 cells, MCF-7 cells |
| Positive IHC detected in | human colon cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:8000 |
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
发表文章中的应用
| WB | See 8 publications below |
产品信息
29450-1-AP targets BRCA2 in WB, IHC, ELISA applications and shows reactivity with human samples.
| 经测试应用 | WB, IHC, ELISA Application Description |
| 文献引用应用 | WB |
| 经测试反应性 | human |
| 文献引用反应性 | human |
| 免疫原 |
CatNo: Ag31064 Product name: Recombinant human BRCA2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 210-388 aa of NM_000059 Sequence: IVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVV 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | breast cancer 2, early onset |
| 别名 | BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD |
| 计算分子量 | 384 kDa |
| 观测分子量 | 384 kDa |
| GenBank蛋白编号 | NM_000059 |
| 基因名称 | BRCA2 |
| Gene ID (NCBI) | 675 |
| RRID | AB_2918309 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | P51587 |
| 储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| 储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for BRCA2 antibody 29450-1-AP | Download protocol |
| IHC protocol for BRCA2 antibody 29450-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Int J Mol Sci CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin | ||
Aging (Albany NY) A prognostic risk model for programmed cell death and revealing TRIB3 as a promising apoptosis suppressor in renal cell carcinoma | ||
Nucleic Acids Res CSB and SMARCAL1 compete for RPA32 at stalled forks and differentially control the fate of stalled forks in BRCA2-deficient cells | ||
J Enzyme Inhib Med Chem Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells | ||
Oncol Lett Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation | ||
Am J Physiol Cell Physiol Synergistic Effects of Olaparib and Palbociclib in Resistant epithelial ovarian cancer |